Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia

Psychiatric Services

Volumn 59, Issue 3, 2008, Pages 315-317

  Zhu, Baojin ^a   Ascher Svanum, Haya ^a   Shi, Lizheng ^b   Faries, Douglas ^a   Montgomery, William ^a   Marder, Stephen R ^c  

^a ELI LILLY AND COMPANY   (United States)

^b TULANE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; HALOPERIDOL DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; BOOTSTRAPPING; CLINICAL TRIAL; DRUG FORMULATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL CARE; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; SCHIZOPHRENIA; DELAYED RELEASE FORMULATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; TIME;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FLUPHENAZINE; HALOPERIDOL; HUMANS; KAPLAN-MEIERS ESTIMATE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 85047685926     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.3.315     Document Type: Article

References (10)

1. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
2. Schooler NR: Relapse and rehospitaliza-tion: comparing oral and depot antipsychotics. Journal of Clinical Psychiatry 64 (suppl16):14-17, 2003
3. Adams CE, Fenton MK, Quraishi S, et al: Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179:290-299, 2001
4. Chue P, Eerdekens M, Augustyns I, et al: Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsychopharmacology 15:111-117, 2005
5. Ascher-Svanum H, Zhu B, Faries D, et al: Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 6:8, 2006
6. Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63:892-909, 2002
7. Tiihonen J, Walhbeck K, Lonnqvist J, et al: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333:224, 2006
8. Haro JM, Novick D, Belger M, et al: Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. European Psychiatry 21:41-47, 2006
9. Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3:21, 2005
10. Svarstad BL, Shireman TI, Sweeney JK: Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatric Services 52:805-811, 2001